Brief: Sequana Medical Raised 27.5 Million Euros In An IPO On Euronext Brussels

Sequana Medical NV

04/04/2019 06:30

April 4 (Reuters) - SEQUANA MEDICAL NV  SEQUA.BR :
    * SUCCESSFULLY RAISED EUR 27.5 MILLION IN AN INITIAL PUBLIC
OFFERING ON EURONEXT BRUSSELS
    * EXPECTS TO START TWO PROSPECTIVE ALFAPUMP CLINICAL STUDIES
IN Q2
OF 2019
    * IN SECOND HALF OF 2019, COMPANY EXPECTS TO RECEIVE
REIMBURSEMENT
OF ALFAPUMP IN NETHERLANDS
    * INTERIM RESULTS FROM SINGLE DOSE FIRST-IN-HUMAN DSR
THERAPY
STUDY ARE EXPECTED TO BE REPORTED DURING Q2 OF 2019
    * FINAL RESULTS FROM THIS STUDY ARE EXPECTED IN SECOND HALF
OF
2019
    * REPEATED DOSE FIRST-IN-HUMAN STUDY OF ALFAPUMP DSR IN
PATIENTS
WITH VOLUME OVERLOAD DUE TO HEART FAILURE IS PLANNED TO BEGIN IN
SECOND HALF OF THIS YEAR
    * REPEATED DOSE FIRST-IN-HUMAN STUDY OF ALFAPUMP DSR IN
PATIENTS
WITH VOLUME OVERLOAD DUE TO HEART FAILURE INITIAL RESULTS
EXPECTED BY YEAR-END
    * EXPECTS RESULTS OF INVESTMENTS IN EUROPEAN COMMERCIAL TEAM
TO
RESULT IN GROWTH OF REVENUES VERSUS 2018
    * APPOINTED PIERRE CHAUVINEAU AS INDEPENDENT CHAIRMAN AND
WIM
OTTEVAERE AS AN INDEPENDENT NON-EXECUTIVE DIRECTOR
    * RECEIVED BREAKTHROUGH DEVICE DESIGNATION FROM THE U.S.
FOOD AND
DRUG ADMINISTRATION (FDA) FOR THE ALFAPUMP

Source text for Eikon:  ID:nGNE78LkzZ 
Further company coverage:  SEQUA.BR 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))